Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

Item

http://www.wikidata.org/entity/Q47854770

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

@en

Neurological Complications Associated With Anti-Programmed Death 1

@nl

type

Item

label

Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

@en

Neurological Complications Associated With Anti-Programmed Death 1

@nl

prefLabel

Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

@en

Neurological Complications Associated With Anti-Programmed Death 1

@nl

P1476

Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

@en

P2093

Bing Liao

http://www.w3.org/2001/XMLSchema#string

Heidi Finnes

http://www.w3.org/2001/XMLSchema#string

Julie E Hammack

http://www.w3.org/2001/XMLSchema#string

Justin C Kao

http://www.w3.org/2001/XMLSchema#string

Michelle L Mauermann

http://www.w3.org/2001/XMLSchema#string

Nathan P Staff

http://www.w3.org/2001/XMLSchema#string

Paola Sandroni

http://www.w3.org/2001/XMLSchema#string

Svetomir N Markovic

http://www.w3.org/2001/XMLSchema#string

Teerin Liewluck

http://www.w3.org/2001/XMLSchema#string

P2860

The blockade of immune checkpoints in cancer immunotherapy

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Lambrolizumab induced central nervous system (CNS) toxicity.

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.

Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis.

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.

P304

1216-1222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMANEUROL.2017.1912

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christopher J. Klein

Elie Naddaf

P577

2017-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28873125

http://www.w3.org/2001/XMLSchema#string

P932

5710300

http://www.w3.org/2001/XMLSchema#string